Wang Y.-K.,Cellular and Molecular Laboratory |
Zhou J.-H.,Cellular and Molecular Laboratory |
Zeng F.,Cellular and Molecular Laboratory |
Zhou S.-Q.,Cellular and Molecular Laboratory |
And 2 more authors.
Acta Anatomica Sinica | Year: 2011
Objective: The objective of this study is to investigate the methylation status of zonula occluden-1 (ZO-1) gene in patients with non-small cell lung cancer (NSCLC) and to indentify this roles in pathogenesis, development and classification of NSCLC. Methods: The methylation status of ZO-1 gene of 101 patients with NSCLC and 61 patients with benign lung disease were detected by methylationspecific-polymerase chain reaction (MS-PCR). ZO-1 mRNA and protein of 200 unmethylation tissue and 62 methylation tissue were detected by real-time PCR and Western blotting separately. Result: Both of ZO-1 mRNA and protein was significant statistic different between methylation group and unmethylation group(t= -26.028, P < 0.01, t = -37.216, P < 0.01). There was significant statistic difference between carcinoma tissue group (32.7%, 33/100) and control group (11.5%, 7/61) (χ2 = 9.190, P < 0.01). ZO-1 promoter methylation status in adjacent tissues was significant statistic different between lymph node invasion group(35.5%, 11/31) and lymph nodes without invasion group(17.1%, 12/70) (χ2 = 4.110, P < 0.05). ZO-1 promoter methylation status of carcinoma tissues wase significant statistic different between 2-year suvival group (27.5%, 14/51) and 2-year death group (43.2%, 19/44) (χ2 =4.150, P < 0.05). Conclusion: Methylation status of ZO-1 promoter may affect the transcription of mRNA and expression of protein. ZO-1 promoter methylation status of adjacent tissues and carcinoma tissues in NSCLC patients may be supposed to forecast the lymph node invasion and 2-year survival rate separately. Source